Project Grant HT94252410129
Award Date
4/15/24
Completion Date
4/18/24
Dollars Obligated
$986K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,316,000.00 to The Trustees of Columbia University in the City of New York to advance the WRN protein as a promising therapeutic target for microsatellite instability-high (MSI-H) cancers. The award runs from August 1, 2025 through July 31, 2029, supporting cutting-edge biomedical research to transform healthcare for military...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,128,000 Project Grant to The Institute For Cancer Research to conduct research on "Restoring PALB2 Function as a Mechanism of PARP1 Resistance in BRCA1-Mutant EOC". The award, with a performance period from July 1, 2024 to June 30, 2028, supports innovative scientific research aimed at improving health outcomes for military service members, veterans, and the broader...
This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,480,500.00 to The Trustees of Columbia University in the City of New York to develop a peptide-based drug delivery system targeting metastatic prostate cancer. The project will run from September 15, 2023 to September 14, 2026. The Department of Defense grant supports basic, applied, and advanced biomedical research with the goal of transforming healthcare for...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,645,000.00 to The Trustees of Columbia University in the City of New York to conduct research on treating HER2 therapy-resistant brain metastasis using antidepressants. The award has a performance period from July 1, 2025 to June 30, 2028. As a prominent academic research institution, Columbia University will leverage its extensive...
The Defense Health Agency awarded a $658,000 Project Grant to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "OVERCOMING IMMUNOTHERAPY RESISTANCE IN CCNE1-AMPLIFIED STOMACH CANCER", is intended to support research to improve treatment options for stomach cancer patients. The 3-year project will run from May 1, 2024 to April 30, 2027....
The Trustees of Columbia University in the City of New York (Columbia University) was awarded a $658,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2026 targeting inflammatory signals as therapeutic strategies for peripheral T-cell lymphoma. Through this award, Columbia University will investigate medical solutions for lymphoma, a type of cancer...
The Trustees of Columbia University in the City of New York received a three-year, $729,000 Project Grant award from the Department of the Army Medical Command. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care. Under this award, Columbia University will conduct research from March 2021 to February 2024 to decipher the mechanisms that drive breast...
The Trustees of Columbia University in New York City will receive $486,000 under a two-year Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program. The grant will fund research into novel regulators of lineage plasticity in castration-resistant prostate cancer. Through this funding, Columbia University researchers will investigate medical solutions for prostate cancer that persists despite hormone therapy, with the goal of transforming...
The Trustees of Columbia University in New York City will receive $729,000 from the Department of the Army Medical Command under a three-year Project Grant award titled "Eliminating Minimal Residual Disease After Targeted Therapy in Breast Cancer." The grant is part of the Military Medical Research and Development program administered by the agency, with a focus on transforming health care for service members and the public through innovative biomedical research. Under the award,...
This federal Project Grant award, with an ID of HT94252510108, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $610,656 award will fund research conducted by The Trustees of Columbia University in the City of New York, Health Sciences Division, to decipher the epigenetic mechanisms that dictate poor responses to KRAS inhibition in lung cancer. The award has a performance period from March 1, 2025 to February 29, 2028. The...